People Living With HIV Clinical Trial
— GANYMEDEOfficial title:
HIV Acquisition and Life Course of Born-abroad Men Who Have Sex With Men Living in Ile-de-France: the GANYMEDE Study
NCT number | NCT04684758 |
Other study ID # | ANRS 14058 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | April 14, 2021 |
Est. completion date | June 30, 2022 |
Verified date | July 2022 |
Source | ANRS, Emerging Infectious Diseases |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
In France, men who have sex with men (MSM) born abroad are the most affected population by HIV, in terms of HIV incidence and prevalence of undiagnosed infections. Close to 50% of born-abroad HIV-infected MSM are living in the region of Ile-de-France, which is the metropolitan area of Paris. Recent European data, not including France, suggest that born-abroad MSM have the highest rate of post-migration HIV acquisition. Many vulnerability factors could explain le burden of HIV in this group of the population. A better understanding of vulnerability factors related to post-migration HIV acquisition should allow to improve HIV prevention and screening strategies among born-abroad MSM living in France. This, in turn, should reduce the burden of HIV in this population in France.
Status | Completed |
Enrollment | 1048 |
Est. completion date | June 30, 2022 |
Est. primary completion date | June 30, 2022 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 18 Years to 99 Years |
Eligibility | Inclusion Criteria: - Cis-gender men who report having sex with men; - Over 18 years of age; - Type 1 HIV infected; - Born in a country other than France and arrived in France at the age of 15 at the earliest; - Followed in Ile-de-France for their HIV infection and having consulted at least once in the participating center during the last 12 months; - Non-opposition to the collection of their health data, after being well informed of the study and the patient rights in accordance with RGPD and LIL (French regulation) Exclusion Criteria: - Somatic or psychiatric pathology making it impossible to participate in an investigation; - Communication disorder making it impossible to read (or oral responses in the event of assisted questionnaire completion). |
Country | Name | City | State |
---|---|---|---|
France | Hôpital Pitié-Salpêtrière, AP-HP, Institut Pierre Louis d'Épidémiologie et de Santé Publique (iPLESP), INSERM 1136 | Paris |
Lead Sponsor | Collaborator |
---|---|
ANRS, Emerging Infectious Diseases | Institut National de la Santé Et de la Recherche Médicale, France |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Phylogenetic analysis in participants having acquired HIV before and after the migration, between them and with other populations | Comparing the viral sequence from participant samples, will allow to estimate the proportion of viral sequences included in viral clusters comprising viral sequences from patients born in France and born outside France (proportion of participants, n (%)) | Through study completion, an average of 12 months | |
Other | Motivations and migratory processes | Analyses of participant questionnaires, will identify the motivations and the migratory processes in the global context of the country of origin (proportion of participants per item, based on responses to questionnaire, n (%)) | Through study completion, an average of 12 months | |
Other | Vulnerability factors | To determine the vulnerability factors for HIV infection, including social inequalities in health, in the country of origin, during the migration, and in France (proportion of participants per item, based on responses to questionnaire, n (%)) | Through study completion, an average of 12 months | |
Other | Health contacts | Description of health contacts, if any, with health system before HIV diagnosis (proportion of participants per item, based on responses to questionnaire (%)) | Through study completion, an average of 12 months | |
Other | Missed opportunities of pre-exposure prophylaxis | Description of missed opportunities of pre-exposure prophylaxis access (proportion of participants per item, based on responses to questionnaire, n (%)) | Through study completion, an average of 12 months | |
Other | HIV healthcare | Description of HIV care, including antiretroviral treatment and viral suppression coverage (proportion of participants, n (%)) | Through study completion, an average of 12 months | |
Primary | Post-migration proportion of HIV acquisition in born-abroad HIV-positive MSM living in Ile-de-France | Estimation of the post-migration proportion of HIV acquisition in born-abroad HIV-positive MSM living in Ile-de-France (proportion of participants, n (%)) | Through study completion, an average of 12 months | |
Secondary | Timing of HIV infection for people infected in France | Estimation of the timing of HIV infection for people infected in France (years, median, IQR) | Through study completion, an average of 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05362916 -
Letermovir in ART-treated HIV-infected Persons
|
N/A | |
Recruiting |
NCT05085145 -
Immunogenicity and Safety of COVID-19 Vaccine in People Living With HIV
|
Phase 4 | |
Recruiting |
NCT05123144 -
A Hybrid Type II Trial of the Optimizing Resilience and Coping With HIV Through Internet Delivery in Ryan White Clinics in Chicago
|
Phase 2 |